Nektar Therapeutics
455 Mission Bay Blvd South
San Francisco
California
94158
United States
Tel: 415-482-5300
Website: http://www.nektar.com/
Email: iaffairs@nektar.com
About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer and auto-immune disease. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new drug candidates. Our success is rooted in four key elements: our track record reflected by a portfolio of successful approved medicines which emanated from our chemistry platform and are made available globally by our pharmaceutical partners, our unique research and development pipeline of new investigational medicines in cancer and immunology, our proprietary and proven science and technology approach that fuels our discovery efforts and our team of dedicated scientists, clinicians and employees focused on bringing new medicines to patients with debilitating diseases.
Stock Symbol: NKTR
Stock Exchange: NASDAQ
465 articles about Nektar Therapeutics
-
New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar Therapeutics' Innovative Small Molecule PEG-Oncolytics
6/3/2008
-
Nektar Therapeutics Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
6/2/2008
-
Nektar Therapeutics to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
5/30/2008
-
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
5/22/2008
-
Bayer AG's Inhaler Drug Gets Thumbs Up in Test
5/20/2008
-
Nektar Therapeutics Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors
5/19/2008
-
Nektar Therapeutics Amikacin Inhale Shows Promising Results in Phase II Study
5/19/2008
-
Nektar Therapeutics Receives Patent Covering Pulmonary Targeted Antibiotics
5/8/2008
-
Nektar Therapeutics Announces First Quarter 2008 Results
5/8/2008
-
Nektar Therapeutics NKTR-118 Shows Substantial Oral Bioavailability and Extended Half-Life in Phase 1 Clinical Data Presented at American Pain Society Meeting
5/7/2008
-
Nektar Therapeutics Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at American Association for Cancer Research Meeting
4/14/2008
-
Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
4/10/2008
-
Nektar Therapeutics Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies; Pfizer Inc. Warns of Lung Cancer with Inhaled Insulin
4/9/2008
-
Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
2/28/2008
-
Nektar Therapeutics to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
2/22/2008
-
West Concludes Agreement with Nektar Therapeutics; Expects to Recover Investments in Dedicated Assets
2/14/2008
-
Nektar Therapeutics Cuts 20% Jobs, COO to Leave Company
2/12/2008
-
Nektar Therapeutics Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Company's Board of Directors Huh To Step Down as COO and Head of PEGylation Business Unit
2/12/2008
-
Nektar Therapeutics (Jobs) and Bayer AG Sign Inhaled Antibiotic Agreement; Bayer to Pay as Much as $125 Million
8/6/2007
-
Nektar Therapeutics Initiates Phase 1 Clinical Program Evaluating NKTR-102 (PEG-irinotecan) for Potential to Treat Patients with Refractory Solid Tumors
3/13/2007